Last updated on September 2018

A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa


Brief description of study

Primary end point: To determine the safety and tolerability of INCB054707.

Key Secondary end point: To determine the systemic exposure to INCB054707 and to determine the efficacy of INCB054707.

Overall design: Population: Men and women aged 18 to 75 years with moderate to severe HS for at least 6 months.

Number of Participants: The study includes 3 cohorts and approximately 36 participants will be enrolled. In each cohort, approximately 12 participants will be randomized 3:1 (INCB054707:placebo) to 1 of 2 treatment groups.

Study Design: Randomized, dose escalation, placebo-control

Estimated Duration of Study Participation: The study will consist of a screening period of up to 28 days, an 8-week treatment period, and a 30-day safety follow-up period. The estimated total duration of study participation is approximately 16 weeks for each participant.

Clinical Study Identifier: TX211866

Contact Investigators or Research Sites near you

Start Over

Marie-Pier Devost

DermEffects
London, Ontario Canada
  Connect »

Marie-Pier Devost

Windsor Clinical Research, Inc
Windsor, Ontario Canada
  Connect »

Marie-Pier Devost

Brunswick Dermatology Center
Fredericton, New Brunswick Canada
  Connect »

Marie-Pier Devost

York Dermatology Center
Richmond Hill, Ontario Canada
  Connect »

Marie-Pier Devost

Lynderm Research Inc.
Markham, Ontario Canada
  Connect »

Marie-Pier Devost

Dr Isabelle Delorme Inc.
Drummondville, Quebec Canada
  Connect »

Marie-Pier Devost

Dre Angelique Gagne-Henley MD inc.
St-Jerome, Quebec Canada
  Connect »

Marie-Pier Devost

SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario Canada
  Connect »

Marie-Pier Devost

Wiseman Dermatology Research
Winnipeg, Manitoba Canada
  Connect »